Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Delgado, K. Thomson, N. Russell, J. Ewing, W. Stewart, G. Cook, S. Devereux, R. Lovell, R. Chopra, D. Marks, S. Mackinnon, D. Milligan (2006)
Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study.Blood, 107 4
P. Dreger, H. Döhner, M. Ritgen, S. Böttcher, R. Busch, S. Dietrich, D. Bunjes, S. Cohen, J. Schubert, U. Hegenbart, D. Beelen, M. Zeis, M. Stadler, J. Hasenkamp, L. Uharek, C. Scheid, Andreas Humpe, T. Zenz, D. Winkler, M. Hallek, M. Kneba, N. Schmitz, S. Stilgenbauer (2010)
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.Blood, 116 14
M. Ritgen, S. Böttcher, S. Stilgenbauer, D. Bunjes, J. Schubert, S. Cohen, A Humpe, M. Hallek, M. Kneba, N. Schmitz, H. Döhner, P. Dreger (2008)
Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trialLeukemia, 22
A. Rawstron, N. Villamor, M. Ritgen, S. Böttcher, P. Ghia, J. Zehnder, G. Lozanski, D. Colomer, C. Moreno, M. Geuna, P. Evans, Y. Natkunam, S. Coutre, E. Avery, L. Rassenti, T. Kipps, F. Caligaris‐cappio, M. Kneba, J. Byrd, M. Hallek, E. Montserrat, P. Hillmen (2007)
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaLeukemia, 21
O. Horký, Jiří Mayer, L. Kablásková, F. Rázga, Marta Krejčí, Jarmila Kissová, M. Borsky, I. Jeziskova, D. Dvorakova (2011)
Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapseInternational Journal of Laboratory Hematology, 33
H. Shulman, K. Sullivan, P. Weiden, G. McDonald, G. Striker, G. Sale, R. Hackman, Tsoi Ms, R. Storb, E. Thomas (1980)
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.The American journal of medicine, 69 2
M. Doubek, J. Mayer, P. Obrtlíková, L. Smolej, E. Cmunt, J. Schwarz, M. Brejcha, Petr Kozmon, Š. Pospíšilová, Y. Brychtova, Z. Pospíšil, M. Trněný (2011)
Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practiceEuropean Journal of Haematology, 87
L. Farina, C. Carniti, A. Dodero, Antonio Vendramin, Anna Raganato, F. Spina, F. Patriarca, F. Narni, F. Benedetti, A. Olivieri, P. Corradini (2009)
Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantationHaematologica, 94
J. Finke, W. Bethge, C. Schmoor, H. Ottinger, M. Stelljes, A. Zander, L. Volin, T. Ruutu, D. Heim, R. Schwerdtfeger, K. Kolbe, J. Mayer, J. Maertens, W. Linkesch, E. Holler, V. Koza, M. Bornhäuser, H. Einsele, H. Kolb, H. Bertz, M. Egger, O. Grishina, G. Socié (2009)
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.The Lancet. Oncology, 10 9
P. Dreger, P. Corradini, E. Kimby, M. Michallet, D. Milligan, J. Schetelig, W. Wiktor-Jedrzejczak, D. Niederwieser, M. Hallek, E. Montserrat (2007)
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensusLeukemia, 21
M. Sorror, B. Storer, B. Sandmaier, M. Maris, J. Shizuru, R. Maziarz, E. Agura, T. Chauncey, M. Pulsipher, P. Mcsweeney, J. Wade, B. Bruno, A. Langston, J. Radich, D. Niederwieser, K. Blume, R. Storb, D. Maloney (2008)
Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 30
I. Khouri, R. Saliba, J. Admirand, S. O'brien, Ming-Sheng Lee, M. Korbling, B. Samuels, S. Giralt, De Lima, M. Keating, R. Champlin, C. Bueso-Ramos (2007)
Graft‐versus‐leukaemia effect after non‐myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP‐70 in refractory chronic lymphocytic leukaemiaBritish Journal of Haematology, 137
G. Banna, S. Aversa, V. Sileni, A. Favaretto, C. Ghiotto, S. Monfardini (2004)
Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.Critical reviews in oncology/hematology, 51 3
V. Valkova, Jiri Schwarz, A. Vítek, M. Marková, D. Pohlreich, K. Benešová, K. Michalová, P. Cetkovský, Marek Trněný (2011)
The effect of allogeneic stem cell transplantation on high risk chronic lymphocytic leukaemia: a single centre retrospective analysisHematological Oncology, 29
R. Ambinder (2009)
The same but different: autologous hematopoietic stem cell transplantation for patients with lymphoma and HIV infectionBone Marrow Transplantation, 44
T Lion (2003)
Summary: reports on quantitative analysis of chimerim after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detectionLeukemia, 17
D. Przepiorka, D. Weisdorf, P. Martin, H. Klingemann, P. Beatty, J. Hows, E. Thomas (1995)
1994 Consensus Conference on Acute GVHD Grading.Bone marrow transplantation, 15 6
M. Hallek, B. Cheson, D. Catovsky, F. Caligaris‐cappio, G. Dighiero, H. Döhner, P. Hillmen, M. Keating, E. Montserrat, K. Rai, T. Kipps (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.Blood, 111 12
C. Moreno, N. Villamor, D. Colomer, J. Esteve, E. Giné, A. Muntañola, E. Campo, F. Bosch, E. Montserrat (2005)
Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia.Blood, 107 11
C. Schmid, M. Schleuning, G. Ledderose, J. Tischer, H. Kolb (2005)
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 24
P. Dreger, R. Brand, D. Milligan, P. Corradini, J. Finke, G. Deliliers, R. Martino, N. Russell, A. Biezen, M. Michallet, D. Niederwieser, on Ebmt (2005)
Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysisLeukemia, 19
H. Kreyenberg, W. Hölle, S. Möhrle, D. Niethammer, Peter Bader (2003)
Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Tuebingen experienceLeukemia, 17
P. Ljungman, M. Bregni, M. Brune, J. Cornelissen, T. Witte, G. Dini, Hermann Einsele, H. Gaspar, A. Gratwohl, Jakob Passweg, C. Peters, V. Rocha, R. Saccardi, H. Schouten, A. Sureda, A. Tichelli, A. Velardi, D. Niederwieser (2010)
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009Bone Marrow Transplantation, 45
Ulrike Koehl, Olaf Beck, Ruth Esser, Erhard Seifried, T. Klingebiel, Dirk Schwabe, Christian Seidl (2003)
Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Frankfurt experienceLeukemia, 17
A. Tsimberidou, W. Wierda, W. Plunkett, R. Kurzrock, S. O'brien, S. Wen, A. Ferrajoli, F. Ravandi-Kashani, G. Garcia-Manero, Z. Estrov, T. Kipps, Jennifer Brown, Albert Fiorentino, S. Lerner, H. Kantarjian, M. Keating (2008)
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 2
J. Delgado, D. Milligan, P. Dreger (2009)
Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?Blood, 114 13
W. Krüger, J. Bohlius, O. Cornely, Hermann Einsele, H. Hebart, G. Massenkeil, S. Schüttrumpf, G. Silling, A. Ullmann, D. Waldschmidt, H. Wolf (2005)
Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the german society of haematology and oncology.Annals of oncology : official journal of the European Society for Medical Oncology, 16 8
F. Zohren, A. Czibere, I. Bruns, R. Fenk, T. Schroeder, T. Gräf, R. Haas, G. Kobbe (2009)
Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemiaBone Marrow Transplantation, 44
M. Krejci, Y. Brychtova, M. Doubek, Martina Tošková, Z. Ráčil, Z. Kořístek, M. Navrátil, M. Tomíška, O. Horký, V. Sandecká, J. Mayer (2011)
Efficacy and toxicity of the FLAMSA/RIC regimen in 40 patients with high-risk AML: a single centre experience
V. Gandhi, A. Kemena, M. Keating, W. Plunkett (1992)
Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.Cancer research, 52 4
Jennifer Brown, Haesook Kim, Shuli Li, K. Stephans, D. Fisher, C. Cutler, V. Ho, Stephanie Lee, E. Milford, J. Ritz, J. Antin, R. Soiffer, J. Gribben, E. Alyea (2006)
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 12 10
C. Schmid, M. Schleuning, R. Schwerdtfeger, B. Hertenstein, E. Mischak-Weissinger, D. Bunjes, S. Harsdorf, C. Scheid, U. Holtick, H. Greinix, F. Keil, B. Schneider, M. Sandherr, G. Bug, J. Tischer, G. Ledderose, M. Hallek, W. Hiddemann, H. Kolb (2006)
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.Blood, 108 3
Allogeneic stem cell transplantation (SCT) is a treatment option for patients with poor-risk chronic lymphocytic leukemia (CLL). Sequential use of chemotherapy and reduced-intensity conditioning has been proposed to improve the treatment outcomes. Fludarabine (30 mg/m 2 /day) and cytarabine (2 g/m 2 /day) for 4 days (combination of fludarabine with cytarabine; FAraC) were used for cytoreduction. After 3 days of rest, reduced intensity conditioning (RIC) was carried out consisting of 4 Gy total body irradiation, 10–20 mg/kg/day antithymocyte globulin for 3 days, and 40–60 mg/kg/day cyclophosphamide for 2 days. The median time of neutrophil engraftment was 16 days. The most frequent toxicities were grades III/IV infections in 12 of 15 cases and gastrointestinal toxicities in 8 of 15 cases. Remission (complete remission + partial remission) was achieved in 14 of 15 patients (93 %), minimal residual disease negativity according to flowcytometric analysis was observed in 10 patients. Nonrelapse mortality after 1 and 2 years was 7 and 13 %, respectively. After the median follow-up from SCT of 30 months, 80 % of patients were alive (12/15), three patients have died, and three relapses occurred. The FAraC–RIC protocol seems to be a promising approach to the treatment of poor-risk CLL with a high response rate of 93 % and favorable progression-free survival and overall survival of 70 and 85 % at 2 years after SCT, respectively. Other prospective clinical trials are needed to confirm the results of this novel therapeutic strategy.
Annals of Hematology – Springer Journals
Published: Jan 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.